1. Home
  2. KPTI vs RVPH Comparison

KPTI vs RVPH Comparison

Compare KPTI & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • RVPH
  • Stock Information
  • Founded
  • KPTI 2008
  • RVPH 2006
  • Country
  • KPTI United States
  • RVPH United States
  • Employees
  • KPTI N/A
  • RVPH N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • RVPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • KPTI Health Care
  • RVPH Health Care
  • Exchange
  • KPTI Nasdaq
  • RVPH Nasdaq
  • Market Cap
  • KPTI 81.1M
  • RVPH 88.0M
  • IPO Year
  • KPTI 2013
  • RVPH N/A
  • Fundamental
  • Price
  • KPTI $0.62
  • RVPH $2.08
  • Analyst Decision
  • KPTI Strong Buy
  • RVPH Strong Buy
  • Analyst Count
  • KPTI 4
  • RVPH 5
  • Target Price
  • KPTI $5.00
  • RVPH $11.40
  • AVG Volume (30 Days)
  • KPTI 679.6K
  • RVPH 1.6M
  • Earning Date
  • KPTI 02-27-2025
  • RVPH 11-14-2024
  • Dividend Yield
  • KPTI N/A
  • RVPH N/A
  • EPS Growth
  • KPTI N/A
  • RVPH N/A
  • EPS
  • KPTI N/A
  • RVPH N/A
  • Revenue
  • KPTI $148,442,000.00
  • RVPH N/A
  • Revenue This Year
  • KPTI $5.47
  • RVPH N/A
  • Revenue Next Year
  • KPTI $6.33
  • RVPH N/A
  • P/E Ratio
  • KPTI N/A
  • RVPH N/A
  • Revenue Growth
  • KPTI 1.77
  • RVPH N/A
  • 52 Week Low
  • KPTI $0.58
  • RVPH $0.60
  • 52 Week High
  • KPTI $1.70
  • RVPH $4.83
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 41.95
  • RVPH 58.09
  • Support Level
  • KPTI $0.60
  • RVPH $1.97
  • Resistance Level
  • KPTI $0.69
  • RVPH $2.15
  • Average True Range (ATR)
  • KPTI 0.05
  • RVPH 0.15
  • MACD
  • KPTI -0.00
  • RVPH 0.02
  • Stochastic Oscillator
  • KPTI 18.17
  • RVPH 78.74

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: